Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pmlive

- PMLiVE

FDA approves sleep disorder drug for blind people

Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock

The thing about small numbers

Marketers working in orphan drugs need to take a narrower, deeper approach to relationship building, and look to medical centres of excellence

Small diseases need big picture communications

An early commitment to communications planning in rare diseases is worth the risk

- PMLiVE

Infographic: Orphan drug market

A visual guide to the orphan drug and rare disease market for pharma

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

A drug bottle with a 'like' option on the label

05 Social Media: A Health Hazard?

The case to embrace going social

Havas Lynx

He who dares wins

The benefits of including medical experts in your brand planning team

- PMLiVE

EMA: more fee reductions for orphan drugs

Greater incentives introduced for larger companies

The logistics of orphan drugs

Managing a rare disease global access programme, the goal is to minimise risk and get the drug to the patient on time

- PMLiVE

Two firms join Merck Serono’s Israeli bioincubator

Metabomed to focus on cancer while ChanBio is developing treatments for MS

- PMLiVE

Rare disease strategy for the UK launched

Aims to improve understanding and boost research

Shire Basingstoke

Shire snaps up Viropharma to build $2bn rare disease unit

Gains access to Cinryze in expensive but 'strategically sound' deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links